Press Releases

Global Genes® Announces Leadership Transition

October 16, 2020

Global Genes® Announces Leadership Transition

Board Member and RARE Corporate Alliance Co-Chair Craig Martin Steps in as Interim CEO

Aliso Viejo, Calif. (October 16, 2020) – Global Genes® announced today that the board has appointed board member and RARE Corporate Alliance co-chair Craig Martin as interim CEO, replacing Kimberly Haugstad, who stepped down from the role effective October 15.

Craig Martin brings a long history with Global Genes and in rare disease, as well as prior CEO experience to the role.  His affiliation with Global Genes dates back nearly a decade, and he has been involved extensively as a strategic advisor in recent years. In addition, Craig is an active thought leader and advocate on critical issues affecting rare disease patients and innovators.

“We are excited to have Craig step in at this important moment for Global Genes,” said John Crowley, CEO of Amicus Therapeutics and fellow board member. “We’ve maintained strong support for the organization and its core programs, and now we have an opportunity to expand our focus to address timely issues like continuity of care and research, and equity, diversity and inclusion.  With Craig’s leadership, we plan to continue building on recent progress and expand our impact globally.”

Craig has an extensive background in strategy consulting and advocacy in life sciences, biotech, health technology and healthcare. In the months ahead, he intends to focus on integrating existing programs and building and connecting newer initiatives via technology platforms and partnerships – all designed to address emerging priorities and needs, some of which have been accelerated by COVID-19.

“This is both an exciting and pivotal time for the rare disease community,” said Craig.  “There are a lot of of promising advancements in science and technology being developed that could lead to better understanding, diagnosis and treatment of rare diseases. But there are also a few key issues that could harm patients by limiting access to care and treatment. I’m pleased to be working with a talented team at Global Genes to help make sure we keep rare patients’ and communities’ interests and needs front and center at this really important moment.”


About Global Genes®
Global Genes is a 501(c)(3) nonprofit organization that connects, empowers and inspires the rare disease community, with the ultimate goal of eliminating the burdens of rare disease for patients and families everywhere.  We provide hope for the more than 400 million people affected by rare disease around the globe.  We fulfill our mission by helping patients find and build communities, gain access to information and resources, connect to researchers, clinicians, industry, government and other stakeholders, share data and experiences, and stand up, stand out and become effective advocates on their own behalf.  Visit to get involved today.